Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01015222 · ClinicalTrials.gov registry record · Phase 1
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
NCT01015222: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01015222 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 122 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01015222, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
Interventions
- DRUG Bevacizumab
- DRUG Paclitaxel
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2009-11 |
| Est. Completion | 2021-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01015222
The ClinicalTrials.gov registry entry for NCT01015222 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01015222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01015222 about?
NCT01015222 is a clinical study titled "Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies". The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
What is the current status of trial NCT01015222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2009-11. Estimated completion is 2021-05-27.
What interventions are being tested in trial NCT01015222?
The interventions under investigation include: Bevacizumab (DRUG), Paclitaxel (DRUG), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT01015222?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.